
    
      This will be an open label, single group, bridging study. Study subjects will be vaccinated
      with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting
      at 6-12 weeks of age followed by two doses at four-week interval.

      This study was performed in strict accordance with Good Clinical Practice.
    
  